We used an aCGH mini-chip specific to gastric cancer for endoscopic biopsy specimens of gastric cancer to estimate the systemic disease status of the cancer before treatment. We employed the aCGH mini-chip to examine pretherapeutic endoscopic biopsy specimens of 32 gastric cancer lesions from 31 cases. The accuracy levels of the aCGH mini-chip for gastric cancer biopsy specimens were 44% for lymph node metastasis, 80% for liver metastasis, 76% for peritoneal dissemination, and 68% for invasion depth. The aCGH minichip was applicable for endoscopic gastric cancer biopsy specimens. It may contribute the therapeutic decision making with automatic evaluation of systemic gastric cancer disease status. Abbreviation: aCGH, array-based comparative genomic hybridization
Background Background
Since the 1960s, pathological evaluation of endoscopic biopsy specimens has been the standard for the diagnosis of gastric cancer. On the other hand, genomic instabilities such as anomalies of the DNA copy number have been explored as a new field in the study of cancer. From early analysis of aneuploidy using flow cytometry and chromosomal comparative genomic hybridization, array-based comparative genomic hybridization (aCGH) was developed. (1) We have already reported an aCGH mini-chip for gastric cancer which was developed for the evaluation of gastric cancer disease status. (2) Using a DNA genome chip (MacArrayTM Karyo 1400, Macrogen, Korea) to examine 83 surgically resected specimens of gastric cancer, we identified 138 clones closely related to the cancer disease status from a 1440 bacterial artificial chromsome (BAC) clone DNA library.
The aCGH mini-chip might enable the automatic and objective evaluation of the systemic cancer disease status. (fig. 1 ) In 30 patients with gastric cancer, we employed aCGH mini-chip to examine surgically resected gastric cancer specimens, and the accuracy rates were 66.7% for lymph node metastasis, 86.7% for liver metastasis, 86.7% for peritoneal dissemination, 96.7% for invasion depth (T1 or T2 over), and 72.4% for histologic type (intestinal or diffuse).
In the present study, we used an aCGH mini-chip specific to gastric cancer for endoscopic biopsy specimens of gastric cancer to estimate the systemic disease status of the cancer before treatment, and compared the aCGH results and clinicopathological results after resection.
Materials and Methods

From October 2007 through January 2009, we employed the aCGH mini-chip to examine pretherapeutic endoscopic biopsy specimens of 32 gastric cancer lesions from 31 cases at the National Hospital Organization Kanmon Medical Center. This study was approved by the institutional review board. The ages of patients varied from 53 to 97 years (mean 70.5). They consisted of 20 males and 11 females, with 21 early (T1) lesions and 11 advanced (T2 or more) lesions.
In each case, we took one or two biopsy specimens through an endoscope in addition to specimens for histological diagnosis and stored them in a freezer at -20°C until we examined the specimens using an aCGH mini-chip at the Department of Pathology of Yamaguchi University.
A tissue microdissection technique was used to reduce the contamination of samples by normal tissue components for array CGH analyses. Highmolecular-weight DNA was extracted from each microdissected tumor specimen with a DNA extraction kit (SepaGene, Sankojyunyaku Co., Tokyo, Japan) according to the manufacturer's instructions as previously described. 
results results
aCGH analysis using the mini-chip for endosopic biopsy specimens was successfully completed for 78.1% (25 of 32) of the gastric cancer lesions. The incomplete results for 21.9% (7 of 32) of the specimens were due to defects in their freezing. Use of multiple specimens and a moist filter paper supporting the specimens solved this problem.
The accuracy levels of the aCGH mini-chip for gastric cancer biopsy specimens were 44% for lymph node metastasis, 80% for liver metastasis, 76% for peritoneal dissemination, and 68% for invasion depth (T1 or T2 over). (table 1) 
discussion discussion
The results of the present study indicated that our mini-chip aCGH analysis was applicable to endoscopic gastric cancer biopsy specimens. As shown in the present study, it is possible to employ aCGH analysis using biopsy specimens to evaluate the whole disease status of gastric cancer with a very different approach from conventional microscopic examination for local pathological findings. aCGH analysis using a disease-specific miniarray is also expected to be useful for the automatic evaluation of cancer status. It may not only reduce the workload for pathologists but also contribute to therapeutic decision making by physicians and surgeons.
However, in this preliminary study, the accuracy rate was not as high as previous results for surgically resected specimens. (2) Intratumor heterogeneity did not affect the results, as shown in the previous study. However, endoscopic specimens are small and superficial, so intratumor heterogeneity may affect the aCGH results. Tissue microdissection technology is necessary in aCGH analysis because contamination of normal tissue reduces the analytical accuracy.
Recently, the main therapeutic modalities for gastric cancer consist of endoscopic resection, surgical operation and chemotherapy. (4) aCGH analysis may have some clinical impact for the choice of the therapeutic modality and measurement of the outcome in a different way from conventional pathological diagnosis. In the present study, we evaluated conventional clinicopathological factors such as lymph node metastasis, liver metastasis, peritoneal dissemination, and invasion depth. We hope that a mini-chip specific for lymph node metastasis will be useful to help determine whether to choose endoscopic submucosal dissection or natural orifice transluminal surgery for gastric cancer. (5)
conclusion conclusion
The aCGH mini-chip was applicable for endoscopic gastric cancer biopsy specimens. It may reduce the workload of pathologists and contribute the therapeutic decision making of physicians and surgeons with automatic evaluation of systemic gastric cancer disease status. references references
